Addressing prescription opioid overdose: Data support a comprehensive policy approach

JAMA - Journal of the American Medical Association

Volumn 312, Issue 17, 2014, Pages 1733-1734

  Jones, Christopher M ^a   Lurie, Peter ^a   Woodcock, Janet ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCODONE BITARTRATE; NALOXONE PLUS OXYCODONE; OXYCODONE; HYDROCODONE; NARCOTIC ANALGESIC AGENT;

DRUG ABUSE; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL PRACTICE; NOTE; OPIATE ADDICTION; PHYSICIAN; PRESCRIPTION; PUBLIC HEALTH; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; DRUG APPROVAL; DRUG OVERDOSE; OPIOID-RELATED DISORDERS; UNITED STATES;

ANALGESICS, OPIOID; DRUG APPROVAL; DRUG OVERDOSE; HEALTH POLICY; HUMANS; HYDROCODONE; OPIOID-RELATED DISORDERS; PUBLIC HEALTH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84908681882     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.13480     Document Type: Note

References (10)

1. Centers for Disease Control and Prevention (CDC). Addressing Prescription Drug Abuse in the United States, Current Activities and Future Opportunities. CDC website. http://www.cdc.gov/homeandrecreationalsafety/overdose/hhs-rx-abuse.html. 2013. Accessed May 3, 2014.
2. US Food and Drug Administration (FDA). Anesthetic and Analgesic Drug Products Advisory Committee [meeting transcript]. FDA website. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM339619.pdf. December 7, 2012. Accessed September 26, 2014.
3. US Food and Drug Administration (FDA). Draft Guidance for Industry: Abuse-Deterrent Opioids - Evaluation and Labeling. FDA website. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf. Accessed September 26, 2014.
4. Rosenblum A, Parrino M, Schnoll S.H., et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007; 90(1):64-71.
5. Jones CM, Mack KA, Paulozzi LJ Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309(7):657-659.
6. Authority OH. Oregon Prescription Monitoring Program: 2012 Annual Report to the PDMP Advisory Commission. Oregon Health Authority website. http://www.orpdmp.com/orpdmpfiles/PDF-Files/Reports/PDMP-AC-AnnualReport-2012.pdf. Accessed May 31, 2014.
7. Dhalla IA, Mamdani MM, Gomes T, Juurlink DN Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Can Fam Physician. 2011; 57(3):e92-e96.
8. IMS Health. National Prescription Audit, 2014. IMS Health website. https://websolutions.imshealth.com. Data extracted September 1, 2014.
9. Johnson H, Paulozzi L, Porucznik C., Mack K, Herter B; Hal Johnson Consulting and Division of Disease Control and Health Promotion, Florida Department of Health. Decline in drug overdose deaths after state policy changes - Florida, 2010-2012. MMWR Morb Mortal Wkly Rep. 2014; 63 (26):569-574.
10. Franklin GM, Mai J, Turner J., Sullivan M, Wickizer T, Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: impact of the Washington State opioid dosing guideline. Am J Ind Med. 2012; 55(4):325-331.